July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Most viewed in the last 7 days from JAMA Oncology
Apr 3, 2024, 06:05

Most viewed in the last 7 days from JAMA Oncology

JAMA Oncology shared a post on LinkedIn:

“Most viewed in the last 7 days from JAMA Oncology: Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemo immunotherapy?”

Additional information.
Source: JAMA Oncology/LinkedIn